Insulin Resistance Predicts Prognosis in Patients With Subarachnoid Hemorrhage

Pengfei Ding1,2,3, Dingding Zhang1,2,3, Haiping Ling1,2,3

  • 1Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.

PubMed

Insights

Insulin resistance predicts poor outcomes in subarachnoid hemorrhage (SAH) patients. A model combining age, glucose, triglyceride-glucose (TyG) index, and TG/HDL ratio shows high accuracy for prognosis prediction.

Area of Science:

  • Neurology
  • Metabolic Syndrome
  • Medical Prognostics

Background:

  • Subarachnoid hemorrhage (SAH) poses significant mortality risks.
  • Predictive markers for SAH prognosis are crucial for patient management.
  • Insulin resistance (IR) is increasingly recognized for its systemic effects.

Purpose of the Study:

  • To investigate insulin resistance (IR) as a predictor of poor prognosis 3 months post-SAH.
  • To evaluate the predictive value of triglyceride-glucose (TyG) index and TG/HDL ratio for SAH outcomes.

Main Methods:

  • Retrospective analysis of 358 SAH patients (age ≥18) due to ruptured aneurysms.
  • Exclusion of patients with diabetes, specific drug use, or other systemic diseases.
  • Utilized ROC, LASSO, and logistic regression to assess TyG index and TG/HDL ratio as predictors.

Main Results:

  • Poor prognosis group showed higher age, BMI, hypertension, glucose, triglycerides, TyG index, and TG/HDL ratio; lower HDL.
  • Age, glucose, TyG index, and TG/HDL ratio were significant predictors of SAH prognosis.
  • A predictive model incorporating these factors demonstrated high discriminatory power (AUC = 0.80).

Conclusions:

  • Insulin resistance is strongly linked to poor prognosis in SAH patients.
  • A novel prognostic model combining age, glucose, TyG index, and TG/HDL ratio offers clinical utility.
  • This model may guide future therapeutic strategies for SAH.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
142
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150